About this trial
Osteoarthritis (OA) stands out as the most prevalent joint disease. It manifests as a progressive degradation of articular cartilage, new bone growth and often synovial tissue proliferation, resulting in pain and compromised joint functionality, ultimately leading to disability. Misalignment of the lower limb (varus or valgus knees) are recognised as a risk factor for osteoarthritis onset and progression. High tibial osteotomy (HTO) is a surgical technique that allows to shift the load from the affected area to other areas with intact cartilage. Similarly to HTO, braces realign the lower limb, without the need for surgical intervention. These corrective treatments are recommended for the youngest group of patients as it allows them to stay active, as opposed to Total Knee Replacement (TKR). Until today, the effects of braces and HTO on the subchondral bone microstructure and cartilage are not well understood. Investigating these aspects to better understand treatment failures is becoming more and more crucial because global prevalence of knee OA is expected to increase with the ageing of populations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
Chronic symptoms of (early) knee OA.
Misalignment of the lower limb and scheduled for HTO surgery (regardless of the HTO technique used (lateral or medial, closing or opening wedge)) or brace treatment.
Follow-up at UZ Leuven.
Disqualifiers
Acute OA symptoms onset (previous knee injury)
Pregnant women
MRI checklist incomplete or failed
BMI > 30
Trial design
Parallel
Treatments tested in this trial
Photon counting CT scanning (PCCT scanning)
Diagnostic testPhoton Counting CT (PCCT) is a novel imaging technique that allows for in vivo high-resolution imaging of the bone microstructure. It has a large field of view and short scanning time compared to the current gold standard for bone microstructural quantification, High Resolution-peripheral CT (HR-pQCT). PCCT scans are performed at pre-treatment visit, 6 months, 12 months and 24 months post-treatment.
Magnetic resonance imaging (MRI scanning)
Diagnostic testCartilage is typically imaged with MRI for its high content of water. Different MRI sequences allow to quantify anatomical aspects such as cartilage volume and thickness, but also its contents (proteoglycans and collagen). MRI scans are performed at pre-treatment visit, 12 months and 24 months post-treatment.
Gait analysis
Diagnostic testThe load shift after limb realignment will also be measured. Gait analysis (combined with musculoskeletal modelling) will be used to measure joint contact forces and knee joint geometry will be derived from the PCCT and MRI scans. Forces and geometry will be given as input to a Finite Element (FE) model of the knee joint, computing stresses and strains distribution on bone and cartilage. The gait analysis will be performed pre-treatment and 12 months post-treatment.
Treatment groups
Trial outcomes
Primary outcomes
Bone microstructure quantification
Trabecular morphology will be described with the bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb.N).
Mechanical properties in osteoarthritic knees
A PCCT-based finite element (FE) model will be built to estimate bone strength, stiffness and apparent modulus by simulating an axial compression.
Load shift quantification
An FE model, simulating forces acting in the knee joint during physiological walking will be built, deriving such forces from gait analysis.
Secondary outcomes
Proteoglycans quantification
As content of cartilage, proteoglycans will be quantified using a specific MRI sequence at pre-treatment and 12 and 24 months post-treatment. These measurements will be compared with the in silico models prediction through an agreement analysis.
Collagen quantification
As content of cartilage, collagen will be quantified using a specific MRI sequence at pre-treatment and 12 and 24 months post-treatment. These measurements will be compared with the in silico models prediction through an agreement analysis.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.